From DCAT Week 2023: Samsung Biologics Investing $1.5 Bn for New Biomanufacturing Facility
Samsung Biologics, a CDMO of biologics, is investing KRW 1.9 trillion ($1.46 billion) for a new biomanufacturing facility in South Korea, which will be the first plant of the company’s second Bio Campus and its fifth biomanufacturing plant overall. Kevin Sharp, Vice President and Head of Samsung Biologics America–Sales, outlined the expansion at the DCAT Member Company Announcement Forum held on March 20, 2023, at DCAT Week.
Samsung Biologics, a CDMO of biologics, is investing KRW 1.9 trillion ($1.46 billion) for a new biomanufacturing facility in South Korea, which will be the first plant of the company’s second Bio Campus and its fifth biomanufacturing plant overall. Kevin Sharp, Vice President and Head of Samsung Biologics America–Sales, outlined the expansion at the DCAT Member Company Announcement Forum held on March 20, 2023, at DCAT Week.
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO
Share article